Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: PHILLIP FLOTOW who wrote (681)	3/17/1999 9:18:00 AM
From: scaram(o)uche	Respond to of 2001

Techvest has a report out on anti-adhesion therapy. No commentary in this release, but I saw a draft of their first GLIA report and it was quite good....... biz.yahoo.com

To: PHILLIP FLOTOW who wrote (681)	3/17/1999 9:33:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2001

>> The announcement coincides with the publication of a patent application by the Patent Cooperation Treaty (PCT) office regarding the use of monoclonal antibodies directed to the complement component properdin. << I've been wondering if the complement work would lead to a non-neuro program. Now we know why the stock took a dive yesterday.... investors upset with a lack of focus. I am pleased..... yet another development program, and I've made my opinion of the utility of anti-complement approaches earlier in the thread. Humanized monoclonal...... OK, but a mention of Janssen, even a repeat of the last commentary, would have been nice. Not counting Adcons other than -P, the company now has at least five development programs, one of which is in pivotal human trials and one of which has completed single-dose phase I. I suspect that the H(3) news has gotten better and better, and that Oesterling is making a grab for independent pharma. Given their structure and the current mood for M&A, I see nothing but upside from this for risk-loving investors. Another program that addresses huge markets, this one competitive with ALXN, whatever TCEL is now called, and several other companies including pharmas. I'll need to check on the potential advantages of choosing properdin as a target.